Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Glucophage XR Generics Will Be Early Test Of Bristol/FTC Settlement

Executive Summary

The expiration of marketing exclusivity forGlucophage XR will provide an early test of the impact of Bristol-Myers Squibb's settlement with the Federal Trade Commission over Bristol's aggressive patent defense tactics
Advertisement

Related Content

Bristol Renounces Late-Listed Patents Under FTC Settlement
Bristol Renounces Late-Listed Patents Under FTC Settlement
Public Citizen Wants Serzone Pulled; No “Unique” Benefit To Offset Risk
Teva’s Generic Remeron Exclusivity Cut To Five Months By FDA Rules
BuSpar Antitrust Settlement Is Two-Times Sales During Extended Patent Life
Bristol Glucovance Has 1.5% Share; 60% Of Patients Are New To Metformin
Advertisement
UsernamePublicRestriction

Register

PS041435

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel